5-ethyl-2-methylsulfonyl-3H-pyrano[2,3-d]pyrimidine-4,7-dione | 944993-05-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡喃嘧啶类
• 英文名称: 5-ethyl-2-methylsulfonyl-3H-pyrano[2,3-d]pyrimidine-4,7-dione
• CAS: 944993-05-9
• 化学式: C₁₀H₁₀N₂O₅S
• 分子量: 270.266
• InChiKey: NXTMAGCJPKYYRU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.5
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  110
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  4-(三氟甲基)苄醇 、 5-ethyl-2-methylsulfonyl-3H-pyrano[2,3-d]pyrimidine-4,7-dione 在 sodium hydride 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 生成 5-ethyl-2-[[4-(trifluoromethyl)phenyl]methoxy]-3H-pyrano[2,3-d]pyrimidine-4,7-dione
  参考文献：
  名称：

  SAR studies of C2 ethers of 2H-pyrano[2,3-d]pyrimidine-2,4,7(1H,3H)-triones as nicotinic acid receptor (NAR) agonist

  摘要：

  Based on in house screening lead compound 1 for the NAR project, SAR studies have been focused on the modification of the C2 ethers of the pyrimidinedione core structure. In this effort, an unpredictable SAR trend was overcome in the alkyl ether and arylalkyl ether series to identify compound 24 with improved in vitro activity compared to nicotinic acid. More consistent and predictable SAR was achieved in the propargyl ether series. Lead compound 41 was identified with good in vitro and in vivo activity in rat, and much improved rat PK profile. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.12.041
• 作为产物：
  描述：

  5-ethyl-2-thioxo-2,3-dihydro-1h-pyrano[2,3-d]pyrimidine-4,7-dione 在 间氯过氧苯甲酸 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 5-ethyl-2-methylsulfonyl-3H-pyrano[2,3-d]pyrimidine-4,7-dione
  参考文献：
  名称：

  SAR studies of C2 ethers of 2H-pyrano[2,3-d]pyrimidine-2,4,7(1H,3H)-triones as nicotinic acid receptor (NAR) agonist

  摘要：

  Based on in house screening lead compound 1 for the NAR project, SAR studies have been focused on the modification of the C2 ethers of the pyrimidinedione core structure. In this effort, an unpredictable SAR trend was overcome in the alkyl ether and arylalkyl ether series to identify compound 24 with improved in vitro activity compared to nicotinic acid. More consistent and predictable SAR was achieved in the propargyl ether series. Lead compound 41 was identified with good in vitro and in vivo activity in rat, and much improved rat PK profile. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.12.041

文献信息

• Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia
  申请人：Palani Anandan

  公开号：US20070173495A1

  公开（公告）日：2007-07-26

  A compound having the general structure of Formula (I): or a pharmaceutically acceptable salt, solvate, ester, or tautomer thereof, are useful in treating diseases, disorders, or conditions such as metabolic syndrome and dyslipidemia.

  具有通式(I)的化合物，或其药用可接受的盐、溶剂合物、酯或互变异构体，可用于治疗代谢综合征和血脂异常等疾病、疾病或症状。
• US7763623B2
  申请人：——

  公开号：US7763623B2

  公开（公告）日：2010-07-27
• SAR studies of C2 ethers of 2H-pyrano[2,3-d]pyrimidine-2,4,7(1H,3H)-triones as nicotinic acid receptor (NAR) agonist
  作者：Xianhai Huang、Jing Su、Ashwin U. Rao、Haiqun Tang、Wei Zhou、Xiaohong Zhu、Xiao Chen、Zhidan Liu、Ying Huang、Sylvia Degrado、Dong Xiao、Jun Qin、Robert Aslanian、Brian A. McKittrick、Scott Greenfeder、Margaret van Heek、Madhu Chintala、Anandan Palani

  DOI：10.1016/j.bmcl.2011.12.041

  日期：2012.1

  Based on in house screening lead compound 1 for the NAR project, SAR studies have been focused on the modification of the C2 ethers of the pyrimidinedione core structure. In this effort, an unpredictable SAR trend was overcome in the alkyl ether and arylalkyl ether series to identify compound 24 with improved in vitro activity compared to nicotinic acid. More consistent and predictable SAR was achieved in the propargyl ether series. Lead compound 41 was identified with good in vitro and in vivo activity in rat, and much improved rat PK profile. (C) 2011 Elsevier Ltd. All rights reserved.